Compare ZH & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZH | XOMA |
|---|---|---|
| Founded | 2011 | 1981 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 279.7M | 308.6M |
| IPO Year | 2021 | N/A |
| Metric | ZH | XOMA |
|---|---|---|
| Price | $2.60 | $29.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $60.60 |
| AVG Volume (30 Days) | ★ 358.7K | 99.5K |
| Earning Date | 03-25-2026 | 03-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $24.95 |
| Revenue Next Year | N/A | $6.20 |
| P/E Ratio | ★ $20.74 | $29.64 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.68 | $18.40 |
| 52 Week High | $5.55 | $39.92 |
| Indicator | ZH | XOMA |
|---|---|---|
| Relative Strength Index (RSI) | 28.12 | 65.21 |
| Support Level | N/A | $23.92 |
| Resistance Level | $4.53 | $30.79 |
| Average True Range (ATR) | 0.13 | 1.49 |
| MACD | -0.03 | 0.32 |
| Stochastic Oscillator | 1.55 | 74.74 |
Zhihu Inc is predominantly engaged in the operation of one online content community and monetizes through paid membership services, advertising services, content-commerce solutions services, and vocational training in China. It generates revenues from Advertising services, Paid membership services, Content-commerce solutions, and Others. It derives all its revenues within China.
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.